Pulmonary deposition of monodisperse aerosols in patients with chronic obstructive pulmonary disease

Experimental Lung Research

Volumn 29, Issue 7, 2003, Pages 475-484

  Meyer, T ^a   Mullinger B ^a   Sommerer, K ^a   Scheuch, G ^a   Brand, P ^b   Beckmann, H ^c   Haussinger K ^d   Weber, N ^d   Siekmeier, R ^e  

^a InAMed GmbH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c BAYER AG   (Germany)

^d Asklepios Fachkliniken   (Germany)

^e Fed Inst Drugs and Med Devices   (Germany)

Author keywords

1 proteinase deficiency; Aerosol; Chronic obstructive pulmonary disease; Inhalation; Peripheral deposition; Systemic drug delivery

Indexed keywords

ALPHA 1 ANTITRYPSIN; IRON OXIDE; OXIDE; PROTEINASE INHIBITOR;

ADULT; AEROSOL; ARTICLE; BREATHING PATTERN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME DEFICIENCY; FEMALE; FLOW RATE; HUMAN; ISOTOPE LABELING; LUNG CLEARANCE; LUNG DEPOSIT; LUNG FUNCTION; MALE; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; ALPHA 1-ANTITRYPSIN DEFICIENCY; FEMALE; FERRIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; PARTICLE SIZE; PULMONARY ALVEOLI; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TECHNETIUM;

EID: 0141924601     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/01902140303775     Document Type: Article

References (24)

1. Edwards DA, Ben-Jebria A, Langer R: Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol. 1998;84:379-385.
2. Köhler D: Systemic therapy with aerosols. In: Moren F, Dolovich MB, Newhouse M, Newman SP, eds. Aerosols in Medicine. Principles, Diagnosis and Therapy. Holland: Elsevier; 1993;303-319.
3. Adjei A, Gupta P: Pulmonary delivery of therapeutic peptides and proteins. J Controlled Release. 1994;29:361-373.
4. Bendstrup KE, Chambers CB, Jensen JI, Newhouse MT: Lung deposition and clearance of inhaled 99mTc-heparin in healthy volunteers. Am J Respir Crit Care Med. 1999;160:1653-1658.
5. Byron PR, Patton JS: Drug delivery via the respiratory tract. J Aerosol Med. 1993;7:49-75.
6. Diot P, Palmer LB, Smaldone A, DeCelie-Germana J, Grimson R, Smaldone GC: RhDNase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med. 1997;156:1662-1668.
7. Hubbard RC, McElvaney NG, Sellers SE, Healy JT, Czerski DB, Crystal RG: Recombinant DNA-produced α1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with α1-antitrypsin deficiency. J Clin Invest. 1989;84:1349-1354.
8. Vogelmeier C, Kirlath I, Warrington S, Banik N, Ulbrich E, du Bois RM: The intrapulmonary half-life and safety of aerosolized α1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med. 1997;155:536-541.
9. Wolff RK: Safety of inhaled proteins for therapeutic use. J Aerosol Med. 1998;11:197-219.
10. Brand P, Friemel I, Meyer T, Schulz H, Heyder J, Häußinger K: Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharmaceut Sci 2000;89:724-731.
11. Chan TL, Lippman M: Experimental measurements and empirical modeling of the regional deposition of inhaled particles in humans. Am Ind Hyg Assoc J 1980;41:399-409.
12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows . Eur Respir J. 1993;6:5-40.
13. Stahlhofen W, Scheuch G, Bailey MR: Investiagations of retention of inhaled particles in the human bronchial tree. Radiat Protect Dosimet. 1995;60:311-319.
14. Scheuch G, Stahlhofen W, Heyder J: An approach to deposition and clearance measurements in human airways. J Aerosol Med. 1996;9:35-41.
15. Scheuch G: Particle recovery from human conducting airways after shallow aerosol bolus inhalation. J Aerosol Sci. 1994;25:957-973.
16. Stahlhofen W, Koebrich R, Rudolf G, Scheuch G: Short-term and long-term clearance of particles from the upper human respiratory tract as function of particle size. J Aerosol Sci. 1990;21:S407-S410.
17. Möller W, Scheuch G, Sommerer K, Heyder J: Preparation of spherical monodisperse ferromagnetic iron-oxide microparticles between 1 and 5 μm. J Magnet Magn Materials. 2001;225:8-16.
18. International Commission on Radiological Protection (ICRP): Human respiratory model for radiological protection. ICRP Publication 6. Ann ICRP 1994;24:1ff.
19. Kim CS: Aerosol deposition in the lung with obstructed airways. J Aerosol Med. 1989;2:111-120.
20. Schlesinger RB: Biological disposition of airborne particles: basic principles and application to vehicular emissions. In: Health Effects Institute, ed. Air Pollution, the Automobile, and Public Health. Washington DC: National Academy Press; 1988;239-298.
21. Anderson PJ, Dolovich MB: Aerosols as diagnostic tools. J Aerosol Med. 1994;7:77-88.
22. Schulz H, Brand P, Heyder J: Particle Deposition in the Respiratory Tract. Particle-Lung Interactions. New York: Dekker; 2000;229-290.
23. Svartengren M, Sommerer K, Scheuch G, Kohlhäufl M, Heyder J, Falk R, Bergmann R, Hofmann W, Bailey M, Philipson K, Camner P: Comparison of clearance of particles inhaled with bolus and extremely slow inhalation technique. Exp Lung Res. 2001;27:367-386.
24. Gehr P, Im Hof V, Geiser M, Schürch S: The fate of particles deposited in the intrapulmonary conducting airway. J Aerosol Med. 1991;4:349-361.